Prometheus Biosciences Profit Margin

Prometheus Biosciences posts a profit margin of -3732.99% as of March 2023. That compares with -1749.08% in the prior-year period — down 113.4% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Prometheus Biosciences's profit margin was -1749.08%. The latest reading is -3732.99% — a 113.4% year-over-year decrease (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Prometheus Biosciences's -3732.99% is lower that level. That is roughly 26975.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Prometheus Biosciences's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -3732.99% as of March 2023; use YoY and peer views to separate noise from signal.

Context for RXDX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Prometheus Biosciences's other metric pages and overview cover the third.